Kornimate/medical-research-clean huggingface dataset:
effect of kinesio tape on back pain, breastfeeding success and breastfeeding self-efficacy

Conditions: Mothers Who Have Babies Between 0-6 Months and Are Actively Breastfeeding; Mothers Who Complain of Back Pain Due to Breastfeeding (Getting 6 Points or More on VAS in the Mothers' Own Evaluation)

Summary: back pain caused by posture changes and increased weight on the breasts during breastfeeding may negatively affect breastfeeding success and self-efficacy. kinesio tape application, which is an effective and cost-effective method, can provide a more comfortable breastfeeding experience by controlling this pain.

despite the universality of these globally valid recommendations for the promotion of breastfeeding, the frequency and prevalence of breastfeeding rates vary from country to country and even between regions within certain countries. planning and successful implementation of interventions to promote breast milk is possible by controlling both positive and negative factors that affect the success and duration of breastfeeding. in order to control the physical problems associated with breastfeeding, existing approaches in the literature for pain management such as fullness of the breasts due to increased lactation, poor positioning during breastfeeding, backaches. kinesio taping is one of these methods, and since it does not have any pharmacological content, it is a practice that does not have side effects on breastfeeding and lactation.

Eligibility criteria:
inclusion criteria: * mothers who have babies between 0-6 months and are actively breastfeeding * primiparous mothers * mothers who complain of back pain due to breastfeeding (getting 6 points or more on vas in the mothers' own evaluation) exclusion criteria: * mothers with premature babies or babies with congenital anomalies * mothers taking painkillers * mothers diagnosed with posture disorders or skeletal system disorders * mothers whose breastfeeding is contraindicated * mothers whose breast milk has stopped * mothers who have other pain complaints in addition to back pain (such as nipple cracks, mastitis pain, etc.)

Keywords: pain breastfeeding breast milk nursing therapy
the safety and effectiveness of zidovudine (azt) in the treatment of hiv infection in patients with aids and advanced arc

Conditions: HIV Infections

Summary: to obtain information about the long-term safety and toxicity of zidovudine (azt). to ascertain whether interruption/resumption at a lower dosage is the optimal management of azt toxicity. because of the high incidence of toxicity and the relatively short-term follow-up of the patients due to the early ending of the phase ii placebo-controlled experiment, it is valuable to continue to get information on the long-term toxicity of azt.

because of the high incidence of toxicity and the relatively short-term follow-up of the patients due to the early ending of the phase ii placebo-controlled experiment, it is valuable to continue to get information on the long-term toxicity of azt. this study provides azt for 6 months to aids patients who were previously enrolled in the azt treatment ind protocol and to patients who qualify for azt under the drug labeling. patients are randomized to 1 of 2 regimens for management of toxicity.

Eligibility criteria:
inclusion criteria concurrent medication: allowed: * for fever control and mild analgesia, modest doses of aspirin or nonprescription doses of ibuprofen may be used with caution; prolonged (\> 72 hours) administration is not advised without dose supervision. patients must have a documented history of positive hiv antibody by elisa, or positive result by elisa at study entry and be in one of the following categories: * aids patients recovered from one or more episodes of categorically confirmed pneumocystis carinii pneumonia (pcp) who were previously enrolled in the zidovudine (azt) treatment ind protocol. * patients who qualify for azt under the labeling: * (a) patients with a prior episode of cytologically confirmed pcp; (b) patients with a prior episode of any other aids defining opportunistic infection and \ 15 lbs or \> 10 percent of total body weight within the previous 3 months) and \< 200 t4 cells and one or more of the following symptoms: * (1) fever \> 100 degrees f without infectious cause of \> 3 weeks duration; (2) clinical diagnosis of hairy leukoplakia; (3) herpes zoster infection within 3 months of entry; (4) unexplained diarrhea after 3 samples eliminating ova, parasites, cryptosporidia, and mycobacterium avium-intracellulare. note: * kaposi's sarcoma without any of the symptoms listed above, regardless of total t4 lymphocyte count, does not constitute an indication for azt treatment under the labeling. exclusion criteria co-existing condition: * patients whose symptoms do not fit into the categories described in disease status and general inclusion criteria are excluded. concurrent medication: excluded: * acetaminophen.

Keywords: acquired immunodeficiency syndrome aids-related complex zidovudine
elastography in superficial lymphadenopathy

Conditions: Superficial Lymphadenopathy

Summary: evaluation of the role of ultrasound elastography in differentiation between benign and malignant lymph nodes and its additional information over the classic gray scale and color doppler ultrasound.

lymph nodes are part of the body immune system which are located throughout the body including head and neck, armpit, and groin. lymphadenopathy is defined as an abnormality in the size or character of lymph nodes caused by the invasion or propagation of either inflammatory or neoplastic cells into the nodes. the differentiation of malignant from benign lymph nodes is essential because it predicts the patient prognosis and help in the decision making regarding the management plan. on ultrasound, gray scale sonography helps to evaluate nodal morphology, whilst color doppler is used to assess vascular pattern. the qualitative criteria for malignancy were heterogenous hypoechoic cortex, irregular margins, lack of hyperechoic fatty hilum and abnormal blood vessels penetrating the lymph nodes capsule.the avascular or hilar patterns were defined as lns with normal vascularity pattern, and the peripheral or mixed (peripheral and hilar) pattern as lns with abnormal vascularity pattern. on b-mode and color doppler ultrasound, there is no specific criteria for differentiating metastatic lymph nodes from reactive lymph nodes with 100% accuracy. fine-needle aspiration biopsy is the reference standard for differentiating metastatic lymph nodes from reactive lymph nodes. however, restrictions of fine-needle aspiration biopsy are that it is an invasive procedure, and it is not possible to perform for lymph nodes smaller than 5 mm.therefore, a simple, reliable, and non-invasive imaging modality for differentiating malignant lymph nodes is required. ultrasound elastography (ue) is a rather new, non-invasive imaging technique that can be used to depict tissue stiffness and elastic properties. ultrasound elastography (ue) can be divided broadly into 2 groups depending on the type of tissue displacement: 1. strain elastography (se): measures tissue displacements along the axis of an applied force.strain elastography provides semi - quantitative scores based on elastographic pattern (scores based on percentage of stiff area within the lesion) and strain ratio (ratio between the lesion and the background tissue). 2. shear wave elastography (swe): measures a different type of waves that is also produced when tissues are mechanically stimulated. shear wave elastography is also a quantitative method of analysis for elasticity images using shear wave speed (m/s) or elastic modulus (kpa). ultrasound elastography (ue) is easy, rather cheap, non-invasive, and quick to perform, well tolerated by patients, and offers a strong diagnostic power.

Eligibility criteria:
inclusion criteria: • patients presented with enlarged lymph nodes by clinical examination. exclusion criteria: * patients who previously receive any medical treatment or chemo or radiotherapy. * patients who previously underwent fine needle aspiration cytology or biopsy.
effects of elastic tape on pulmonary rehabilitation of patients with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: evaluate the effect of the use of elastic tape in chest wall and abdomen in the physical capacity, psychosocial distress levels, quality of life and anxiety, and depression symptoms of individuals with moderate to very severe chronic obstructive pulmonary disease (copd) undergoing pulmonary rehabilitation.

individuals will be evaluated on two non-consecutive days (7 days apart). on the first visit, wil be obtained: clinical and anthropometric data and assessed clinical control \[copd assessment test™(cat)\], health-related quality of life \[chronic respiratory questionnaire (crq)\], and anxiety and depression levels \[hospital anxiety and depression scale (hads)\]. patients will also perform a complete pulmonary function test. after, the volunteers will receive a triaxial accelerometer to assess their physical activity level (pal) and will be instructed to return after seven days. on the second visit, patients will undergo the incremental shuttle walking test (iswt), and the endurance shuttle walking test (eswt), without et. after the assessments, the individuals will be randomized. randomization will be computer generated (www.randomization.com) by an investigator who will not be involved in individual recruitment, evaluation, or intervention. the allocation of individuals will be secret using consecutive numbered, sealed, and opaque envelopes (concealed allocation). initial and post-intervention assessments will be performed by an investigator who will not be involved in the recruitment, evaluation, or intervention. after inclusion, individuals will start a pulmonary rehabilitation (pr) program for eight weeks; twice a week, individuals in the et group will have the tape applied at the beginning of each session and removed at the end. after completing the 8-week pr period, individuals will undergo the same tests performed in two visits.

Eligibility criteria:
inclusion criteria: * moderate to very severe copd diagnosis according to global iniciative for chronic obstructive lung disease (gold) 2020 * clinical stability (i.e., no exacerbations for at least 30 days) * male * non-obese (bmi ≤29.9 kg/m2) * no musculoskeletal limitation * not included in a pulmonary rehabilitation program in the last 6 months. * do not perform home oxygen therapy exclusion criteria: * present osteoarticular, cognitive, neurological, and/or cardiological dysfunctions that prevent physical training

Keywords: rehabilitation exercise capacity health-related quality of life elastic tape
predictive factors study

Conditions: Acromegaly

Summary: this is a long term study to evaluate common therapeutic algorithms and possible predictive parameters for somatuline autogel treatment in patients with acromegaly.


Eligibility criteria:
inclusion criteria: * diagnosis of acromegaly. * males and females aged 18 years and older. * signed informed consent (patient must give consent to the collection of retrospective data). * patients who have had surgery may enter the study 3 months post-surgery and evaluated for the duration of the study. * with the intention to be treated with atg (decision to prescribe atg made prior to inclusion into the study) or already being treated with atg. * if already being treated with atg: previous atg treatment maximum of 3 months. and minimum data available (demographic data, disease history including previous treatments, gh, igf-1 levels at baseline and under treatment as applicable). * not receiving dopamine agonists or other medical therapy (pegvisomant, or other somatostatin analogues) for the treatment or symptom control of acromegaly. exclusion criteria: * the subject has had radiotherapy in the last 5 years. * the subject has had surgery in the last 3 months. * the subject has already been included in this study. * participation in an interventional trial, or receiving experimental drug.
niddm and ir in combination therapy for chc

Conditions: Chronic Hepatitis C; Insulin Resistance

Summary: the influence of insulin sensitivity and glucose tolerance on the effects of antiviral therapy for hcv remains unclear. the aim of the present study was (1) to elucidate the clinical and virological factors associated with sustained viral response in patients with combination therapy with peg-ifn and ribavirin. (2) to clarify the influence of diabetes mellitus (dm), impaired glucose tolerance test (igt) and insulin resistance (ir) on the hcv response to combination therapy with peg-ifn and ribavirin. (3) to test the influence of combination therapy on homa ir

total 300 treatment-naïve chronic hepatitis c patients will be enrolled. the prevalence of niddm, igt and ir will be explored in this hospital-based study among the clinically defined chronic hepatitis c taiwanese. the clinical manifestations of chronic hepatitis c in the biochemical, virological and histopathological aspects will be evaluated. liver enzymes will be measured on a multichannel autoanalyzer. virological markers for hcv including serum hcv rna detected using a standardized automated qualitative pcr assay, hcv rna genotypes determined for genotypes 1a, 1b, 2a, 2b and 3a and serum hcv rna levels measured by using the branched dna assay. the liver histology will be assessed for scoring the disease activity grade quantitatively according to the histological activity index (hai). patients are assigned a diagnosis of dm if there was documented use of oral hypoglycemic medication or insulin, random glucose in excess of 200 mg/dl, or fasting glucose greater than 126 mg/dl on two occasions. a standard oral glucose tolerance test (ogtt) will be performed. in addition to an ogtt, a history of diabetes mellitus by chart review and/or questionnaire will be also obtained. standard antiviral therapy will be carried out with peg-ifn, given subcutaneously weekly plus 1,000-1,200 mg of oral ribavirin daily. patients will receive another 24 week of follow-up period to determine the virological response.

Eligibility criteria:
inclusion criteria: 1. chronic hepatitis c patients with positive anti-hcv for more than 6 months and hcv rna 2. no overt hepatic failure or decompensated liver cirrhosis (child-pugh class b or c) or hepatocellular carcinoma. exclusion criteria: 1. positive for hepatitis b surface antigen (hbsag)or with concomitant human immunodeficiency virus infection 2. with other types of hepatitis including autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, wilson's disease, alpha 1-antitrypsin deficiency 3. current or past history of alcohol abuse (80 ml ethanol per day)

Keywords: chronic hepatitis c diabetes insulin resistance combination therapy
first mobilization protocol for total knee arthroplasty patients

Conditions: Knee Arthroplasty

Summary: this single blinded randomized controlled study evaluates the effect of developed first mobilization protocol applied to knee arthroplasty patients on state anxiety, kinesiophobia, initial mobilization related symptoms.

ensuring the mobilization of patients in the postoperative period, preventing complications resulting from inactivity, maintaining homeostatic balance and accelerating recovery are among the important goals of nursing care. for this reason, it is necessary to gradually increase the patients in line with the evidence-based data and the importance of mobilization should be emphasized. in this study, it was aimed to develop the first mobilization protocol for patients undergoing total knee arthroplasty and to evaluate the effectiveness of the developed protocol on patients' state anxiety, kinesiophobia, initial mobilization related symptoms. the research is planned to be conducted in the orthopedics and traumatology clinic of a university hospital in turkey. the protocol of the study will be completed with78 patients who meet the sampling criteria (39 interventions, 39 controls), although it was designed as a single-center, single-blind randomized controlled and prospective study. patient information form, state-trait anxiety inventory, tampa kinesiophobia scale and initial mobilization-related symptoms evaluation form will be used to collect the data of the study. study; it is a single-center and single-blind randomized controlled experimental study protocol. the data obtained within the scope of the study will be explained after being collected and analyzed. the effectiveness of the first mobilization protocol developed for tolal knee arthroplasty patients will be evaluated.

Eligibility criteria:
inclusion criteria: * 18 years and older, * first time knee arthroplasty surgery, * have not received a diagnosis that will prevent communication, * no physical disability, * mobilized during the implementation process of the research, * bilateral arthroplasty surgery is not performed, exclusion criteria: * revision surgery performed, * patients who have undergone total hip or knee arthroplasty before, * inability to perform or delay mobilization due to complication(s) developed in the postoperative period, * the patient cannot be mobilized on the first postoperative day (in the first 48 hours), * desire to leave the research voluntarily.

Keywords: total knee arthroplasty nursing mobilization ambulation first mobilization protocol orthopaedic and trauma nursing anxiety kinesiophobia mobilization related symptoms
investigation on differences in skin sodium content between normal subjects and icu-patients

Conditions: Hypernatremia

Summary: this study investigates the differens in sodium storage in skin between normal subjects, patients after cardiac surgery and septic patients.

according to the current paradigm icu-acquired hypernatremia is mainly an iatrogenic problem, caused by sodium overload or water deficit. in spite of several interventions to reduce sodium intake and optimize fluid balance, critically ill patients still develop hypernatremia. these patients also seem to have an inability to excrete sodium, hence develop a positive sodium balance. in animals sodium storage in the third compartment was found. our hypothesis is that sodium storage in the third compartment is different in critically ill patients and this difference could play a role in the development of icu-acquired hypernatremia.

Eligibility criteria:
inclusion criteria: * 50-80 years (septic patients), 45-85 years (cabg and hip replacement-patients) * patients undergoing hip replacement: no relevant medical history (i.e. chronic and/or systemic diseases with a suspected influence on sodium / sodium handling) * septic patients: fulfilling the criteria for the systemic inflammatory response syndrome in the presence of a(n expected) new infection exclusion criteria: * absence of both upper legs * skin disease that makes skin biopsies in healthy skin impossible * subjects with in their history formation of exaggerated scar tissue * subjects suffering from psoriasis or lichen ruber * use of skin corticosteroids on all skin of both upper legs \< 2 weeks before inclusion * tattoos covering the whole surface of both upper legs * use of diuretics in the past month * current renal replacement therapy * septic patients: not being sedated * patients undergoing hip replacement: hip replacement because of an inflammatory disease
stellate ganglion block in children with autistic disorder

Conditions: Autistic Disorder

Summary: the goal of this clinical trial is to explore efficacy of stellate ganglion block children with autistic disorder. the main question it aims to answer is: can stellate ganglion block improve the autistic disorder in children? children with autistic disorder will be divided into the control group and experimental group evenly. all the patients were provided with routine therapy, while the patients in the experimental group were given stellate ganglion block. the childhood autism rating scale of the two groups of patients before and after treatment are evaluated.

autistic disorder in children is becoming increasingly more. the goal of this clinical trial is to explore efficacy of stellate ganglion block children with autistic disorder. the main question it aims to answer is: can stellate ganglion block improve the autistic disorder in children? children with autistic disorder will be divided into the control group and experimental group evenly. all the patients were provided with routine therapy, while the patients in the experimental group were given stellate ganglion block. the childhood autism rating scale of the two groups of patients before and after treatment are evaluated.

Eligibility criteria:
inclusion criteria: * diagnosed as autistic disorder. * aged between 4 years old and 8 years old. * no contraindications to stellate ganglion block. exclusion criteria: * other significant physical or neurodevelopmental disorders. * other significant medical conditions
bioequivalence study of torrent pharmaceuticals ltd's alfuzosin er tablets under fed conditions

Conditions: Healthy

Summary: objective: primary objective of the present study was to assess the relative bioavailability of two formulations of extended release alfuzosin 10 mg under fed conditions, in healthy adult male subjects after an oral administration with 7 days washout period. study design: open-label, randomised, two period, two treatment, crossover, single-dose bioequivalence study


Eligibility criteria:
inclusion criteria: * the volunteers were included in the study based on the following criteria: * sex: male. * age: 18 - 45 years. . * volunteer with bmi of 18-27 (inclusive both) kg/m2 with minimum of 50 kg weight. * healthy and willing to participate in the study. * volunteer willing to adhere to the protocol requirements and to provide written informed consent. * non-smokers or smoker who smokes less than 10 cigarettes per day exclusion criteria: * the volunteers were excluded from the study based on the following criteria: * clinically relevant abnormalities in the results of the laboratory screening evaluation. * clinically significant abnormal ecg or chest x-ray. * systolic blood pressure less than 100 mm hg or more than 140 mm hg and diastolic blood pressure less than 60 mm hg or more than 90 mm hg. * pulse rate less than 50/minute or more than 100/minute. * oral temperature less than 95°p or more than 98.6°p. * respiratory rate less than 12/minute or more than 20/minute * history of allergy to the test drug or any drug chemically similar to the drug under investigation. * history of alcohol or drug abuse * positive breath alcohol test * recent history of kidney or liver dysfunction. * history of consumption of prescribed medication since last 14 days or otc medication since last 07 days before beginning of the study. * volunteers suffering from any chronic illness such as arthritis, asthma etc. * history of heart failure. * hiv, hcv, hbsag positive volunteers. * opiate, tetra hydrocannabinol, amphetamine, barbiturates, benzodiazepines, - - - cocaine positive volunteers based on urine test. * volunteers suffering from any psychiatric (acute or chronic) illness requiring medications. * administration of any study drug in the period 0 to 3 months before entry to the study. * history of significant blood loss due to any reason, including blood donation in the past 3 months. * history of pre-existing bleeding disorder. * existence of any surgical or medical condition, which, in the judgment of the chief investigator and/or clinical investigator/physician, might interfere with the absorption, distribution, metabolism or excretion of the drug or likely to compromise the safety of volunteers. * inability to communicate or co-operate due to language problem, poor mental development or impaired cerebral function.